• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Sarah Faulkner

DarioHealth inks U.S. distro deal for digital diabetes management program

January 2, 2019 By Sarah Faulkner

DarioHealth updated

DarioHealth (NSDQ:DRIO) said today that it inked a deal with healthcare products provider Better Living Now for the distribution of its blood glucose monitoring system and the DarioEngage digital health program. According to the terms of the deal, BLN plans to buy DarioHealth’s smart glucose meter and test strips to distribute to its customers. The agreement […]

Filed Under: Diabetes, Featured, mHealth (Mobile Health), Wall Street Beat Tagged With: dariohealth

Report: Pharma companies kick off new year with price hikes

January 2, 2019 By Sarah Faulkner

Prescription drugs

Major pharmaceutical firms started the new year by hiking the prices of hundreds of drugs, according to a new study published by Rx Savings Solutions. First reported in The Wall Street Journal, the study found that the average price increase taken by more than three dozen companies was roughly 6.3%. Allergan (NYSE:AGN) topped the list, raising the […]

Filed Under: Business/Financial News, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Allergan, Biogen, Bristol-Myers Squibb Co., Eli Lilly & Co., Pfizer Inc.

Heron Therapeutics wins priority review for postoperative pain drug

December 31, 2018 By Sarah Faulkner

Heron Therapeutics logo

Shares in Heron Therapeutics (NSDQ:HRTX) rose today after the biotech reported that the FDA gave priority review status to its investigational postoperative pain drug. The company’s HTX-011 product is a long-acting formulation of bupivacaine in combination with the anti-inflammatory meloxicam. Heron touts the product as the first dual-action, fixed-combination drug designed to address postoperative pain […]

Filed Under: Featured, Food & Drug Administration (FDA), Pain Management, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: herontherapeutics

Researchers design ingestible sensor for controlled drug release

December 31, 2018 By Sarah Faulkner

MIT wireless pill

Researchers from MIT, Brigham & Women’s Hospital and Draper have developed a Bluetooth-controlled ingestible capsule that can sense the temperature of its environment and reside in the stomach for at least a month. The device, which was tested in an animal study and composed of 3D-printed parts, is powered by a small silver oxide battery […]

Filed Under: Drug-Device Combinations, Featured, Patient Monitoring, Pharmaceuticals Tagged With: Brigham & Women's Hospital, Draper, Massachusetts Institute of Technology

PolarityTE registers bone repair product with FDA

December 31, 2018 By Sarah Faulkner

PolarityTE updated logo

PolarityTE (NSDQ:PTE) said last week that it registered its bone repair product, OsteoTE, with the FDA. The Utah-based company’s technology is an autologous, homologous product designed to repair, reconstruct and replace bone using a patient’s own cells. In preclinical trials, OsteoTE regenerated bone with similar characteristics to natural bone, according to PolarityTE. The company also […]

Filed Under: Featured, Food & Drug Administration (FDA), Regenerative Medicine, Regulatory/Compliance, Wall Street Beat, Wound Care Tagged With: polarityte

Ocular Therapeutix lands $25m term loan

December 28, 2018 By Sarah Faulkner

Ocular Therapeutix logo

Ocular Therapeutix (NSDQ:OCUL) said today that it closed a refinancing of its existing debt by landing a $25 million term loan with MidCap Financial and Silicon Valley Bank. The 5-year term loan facility expanded the company’s prior $18 million credit facility to $25 million. The proceeds from the loan were used to repay the $12.3 million […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Ocular Therapeutix

FDA deals tentative approval to Braeburn for OUD injection

December 26, 2018 By Sarah Faulkner

Braeburn Pharmaceuticals

Braeburn said this week that it won tentative FDA approval for its Brixadi extended-release weekly and monthly buprenorphine injections. The company’s product is designed for the treatment of moderate to severe opioid use disorder in people who have already started treatment with buprenorphine. The FDA acknowledged that Braeburn met all required quality, safety and efficacy […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance Tagged With: Braeburn Pharmaceuticals

FDA to review Kala’s dry eye disease drug

December 26, 2018 By Sarah Faulkner

Kala Pharmaceuticals - updated logo

Kala Pharmaceuticals (NSDQ:KALA) said today that the FDA accepted the new drug application for Kala’s dry eye disease therapy, KPI-121 0.25%. The two-week treatment features Kala’s mucus-penetrating particle drug-delivery technology and is designed for the temporary relief of sings and symptoms of dry eye disease. The FDA is slated to make a decision about KPI-121 0.25% […]

Filed Under: Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Kala Pharmaceuticals

Acorda wins FDA nod for inhaled Parkinson’s therapy

December 26, 2018 By Sarah Faulkner

Acorda's Inbrija device

Acorda Therapeutics (NSDQ:ACOR) said this week that the FDA approved its Inbrija device for the intermittent treatment of  “off” episodes in people with Parkinson’s disease. The self-administered, inhaled therapy is designed for people experiencing a re-emergence of Parkinson’s symptoms. These “off” episodes are caused by low levels of dopamine between doses of the standard oral Parkinson’s […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Neurological, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Acorda Therapeutics

Delcath inks European licensing deal for Chemosat

December 26, 2018 By Sarah Faulkner

Delcath Systems - updated logo

Delcath Systems (OTC:DCTH) said this week that it inked a licensing deal with Germany-based medac for the commercialization of Chemosat in Europe. According to the terms of the seven-year agreement, Delcath’s European subsidiary will exclusively license its Chemosat system to Medac for sale in the EU, Norway, Liechtenstein, Switzerland and the UK. Medac is slated […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: Delcath Systems Inc.

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Interim pages omitted …
  • Page 241
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS